How to Group Multiple Models of Dental Devices in Overseas Registration

Published: August 25, 2026
Updated: August 25, 2026

Key Summary

Dental device manufacturers often face situations where a single product series includes multiple models. Whether multiple models can be submitted together directly affects registration costs, timelines, and post-market management. Companies should first determine whether the product falls within the scope of medical device regulation in the target country, then identify the registration pathway based on intended use, structural composition, technical characteristics, and risk classification. If all models share the same technical architecture, similar working principles, consistent key performance indicators, and differences do not affect safety and effectiveness, they can generally be filed as a single registration unit.

However, different countries define “same registration unit” differently, with GHWP member states, Southeast Asia, the Middle East, and Latin America each having distinct emphases. Before filing, companies should organize reusable technical documentation, including risk management reports, performance verification, biocompatibility, clinical evaluation or exemption justifications, and confirm local agent, labeling, and post-market surveillance requirements. Common risks include over-consolidating models with significant clinical differences to save effort, or ignoring local requirements for model naming, software versions, and material composition differences.

A rigorous grouping strategy should be based on technical evidence and regulatory applicability in each country; where necessary, split filings and plan coverage relationships between core and derivative models to reduce deficiency risks and post-market change costs.

Applicable Scenarios and Core Questions

Dental devices often appear as product families. For example, a dental implant system may include models with different diameters, lengths, surface treatments, or connection types; dental X-ray equipment may have different output powers or software versions; dental handpieces may be classified by speed, interface, or material. When initiating overseas registration, the first question is whether these models can be submitted as one registration unit or must be filed separately.

This decision is not simply a matter of similar appearance or identical product names. Regulatory authorities in different countries have significantly different principles for defining a “single registration unit,” directly tied to product risk class, clinical evaluation path, and technical documentation structure. If grouping is inappropriate, the consequences range from time-consuming deficiency responses to registration rejection or post-market findings that a marketed model falls outside the approved scope.

This FAQ is intended for dental device manufacturers planning to enter GHWP member states, Southeast Asia, the Middle East, or Latin America, and helps clarify judgment logic, documentation preparation, and common missteps. Companies should develop a clear grouping strategy before starting registration, based on actual product line differences.

Registration Judgment Logic

To determine whether multiple models can be combined into one filing, follow a stepwise approach:

• Step 1: Confirm regulatory scope. Determine whether the product falls under medical device regulation in the target country. Some products may be regulated as medical devices in one jurisdiction but as ordinary consumer goods or health devices in another. Only if the product is regulated as a medical device does the registration unit question arise.
• Step 2: Assess risk classification for each model. In dental devices, invasive implants are typically the highest risk class, while cutting tools or impression materials may be lower risk. All models in one registration unit must share the same risk class. If one model requires clinical evaluation while another is exempt, combining them is generally inappropriate.
• Step 3: Compare structural composition, working principles, key performance indicators, and intended use. If all models are based on the same core technology and differences are limited to dimensions, appearance, or non-critical parameters, a combined filing is feasible. Conversely, substantive differences in materials, sterilization methods, software algorithms, or indications likely require separate filings.
• Step 4: Evaluate reusability of existing registrations. If the company already has NMPA, CE, FDA, ISO 13485, MDSAP, or other market approvals, identify common evidence documents and determine what localization data (e.g., clinical data, label language, test standards) is needed for the target country.
• Step 5: Confirm target-country specifics. GHWP members such as China, Saudi Arabia, Indonesia, Thailand, Vietnam, and Malaysia have different guidance on registration unit division and model coverage. Some allow a “family” as the primary filing with derivative models listed; others require every marketed model to be individually coded or registered.

Materials and Evidence

Regardless of whether a combined or split filing is chosen, complete technical documentation must support the application. The core of multi-model group filing is not “submitting fewer documents” but scientifically demonstrating homology among models.

Required documents include at least:

• Product technical requirements or a performance parameter comparison table clearly outlining similarities and differences among models.
• Risk management report covering all models under the same risk analysis framework.
• Biocompatibility evaluation report, based on the nature and duration of patient or user contact, assessing whether the same dataset can support all models.
• Electrical safety, electromagnetic compatibility, and environmental testing reports, especially for active dental devices.
• Clinical evaluation report or exemption justification. If clinical indications are identical across models and differences do not affect safety or effectiveness, clinical evidence may be shared; otherwise, targeted data is required.

Labels and instructions for use are common deficiency points. In a combined filing, labels must clearly identify each model and avoid vague statements such as “see attachment for model list.” Some countries require all models to be listed in the instructions or labels, or require an explanation of the model naming rule.

Local agent and authorized representative requirements are also part of registration. Several Southeast Asian, Middle Eastern, and Latin American countries require a local registrant, and the agent is responsible for post-market surveillance, adverse event reporting, and certificate maintenance. Companies should select an agent during project initiation and incorporate the agent’s duties into quality system agreements.

Common Mistakes

• Forcing models with material differences in clinical indications into one registration unit, e.g., an implant system used for tooth replacement and a special design for bone defect reconstruction sharing one unit.
• Ignoring how the target country defines “same design” and relying on domestic grouping experience, leading to deficiencies that require splitting and refiling.
• Submitting a superficial product technical requirement or comparison table that lists model names without analyzing the impact of differences on safety and performance.
• Failing to account for software version updates or raw material supplier changes, causing the registration certificate coverage to mismatch actual products.
• Depending on test reports from other markets without verifying that accepted standard versions and test methods align with the target country.
• Failing to confirm local agent capability early, causing delays due to agent changes or insufficient authorization scope.

Enterprise Preparation Checklist

• Establish a product model matrix listing key attributes for each model: structural composition, materials, dimensions, performance parameters, intended use, software version, sterilization method, etc.
• Review target-country regulations and guidance to confirm product risk class and registration pathway.
• Develop a model difference comparison table and conduct a risk impact analysis for each difference.
• Consolidate existing NMPA, CE, FDA, etc., registration documents and evaluate which parts can be reused and which require localization.
• Prepare risk management and clinical evaluation evidence, confirming all models are covered by the same risk framework and clinical dataset.
• Draft labels and instructions for use, checking target-country language, symbols, warnings, and model identification requirements.
• Select and appoint a qualified local agent, sign a service agreement, and define authorized representative and post-market obligations.
• Develop a post-market surveillance plan and change management process to ensure the registration certificate always matches product status.

AIMEILI Perspective

From the perspective of a regulatory consulting firm, we advise companies not to first ask “can we combine?” but rather “how much extra cost does splitting incur, and how high is the deficiency risk if we combine?” The safest approach is to design a “core model + derivative models” coverage strategy for the product family. Use the core model to generate the primary performance and clinical evidence, then include derivative models in the same registration unit or register them separately according to each target country’s rules.

Companies often underestimate local regulatory differences. The same set of models may be covered under a single registration certificate as “specifications/models” in China but may be required to register separately in Indonesia or Saudi Arabia. Therefore, select the target country first, then formulate a grouping plan based on that country’s guidance, rather than adopting a global grouping table upfront.

Reusable documentation includes basic performance testing, biocompatibility, risk management frameworks, and quality management system certificates. Documentation that must be localized includes labels and instructions for use, clinical evaluation or literature search, declarations of conformity, agent information, and in some countries, local testing or registration inspection reports.

Local agent and certificate control are often overlooked. The legal holder of a registration certificate is typically the local agent, not the manufacturer. If the agent changes, the certificate may need re-registration or transfer. Treat the agent relationship as a registration asset and periodically verify the agent’s service and compliance competence.

Multi-country registration also carries the risk of duplicate information compilation and varying formats for each deficiency response. We recommend building a two-tier structure: an “original technical document library” and “country-specific document packages,” so that core information remains stable and repetitive work and deficiency rates are reduced.

Common Follow-up Questions

If multiple models are combined into one filing, does that mean all models are automatically approved?
Not exactly. After a combined filing is approved, the certificate usually lists the covered model range. Some countries list each model code in the approval document, while others recognize only the model naming rule. Companies must verify the certificate attachment to ensure all marketed models are within the covered range.

Can implants made of different materials, such as pure titanium and titanium alloy, be included in the same registration unit?
Such a difference usually directly affects mechanical properties and biocompatibility. Unless strong evidence shows that both materials are equivalent in safety and performance for the same intended use, they should not be combined without further analysis. It is recommended to evaluate risk separately and split the filing if necessary.

If the product is already registered in China, can we directly submit the Chinese dossier for overseas applications?
No, not directly. Technical requirements, clinical evaluation, and testing standards in Chinese registration documents must be converted according to target-country regulations. For example, ISO 10993 biocompatibility tests may be accepted by many countries, but some require local laboratory reports or additional tests. Companies should compare the target country’s document checklist item by item.

Source and Applicability

Content compiled by AIMEILI Regulatory Editorial Department, professionally reviewed by AIMEILI Medical Device International Registration Project Team. Information is based on the AIMEILI regulatory affairs practice database, international medical device registration knowledge base, and public regulatory information; specific projects should be confirmed against the latest requirements of the target country’s regulatory authority and the product dossier.

This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements, testing conclusions, or legal advice of the target country’s regulatory agency.